What stands out about Phibro Animal Health right now

Phibro Animal Health (PAHC) has caught investor attention after a strong 1 year total return of 135.9%, alongside reported annual revenue of US$1.46b and net income of US$92.09 million.

The current share price of US$49.47 reflects a mixed recent pattern, with a 7 day share price return of 3.23% and a 90 day share price return of 23.21%, alongside a 1 year total shareholder return of 135.9% that points to strong momentum over a longer stretch.

If Phibro Animal Health’s run has you rethinking where growth might come from next, it could be worth checking our screener of 18 top founder-led companies as potential new ideas.

With the share price now near the latest analyst target and a model-based estimate suggesting a large intrinsic discount, the key question is whether Phibro still trades below its worth or if the market already prices in future growth.

Most Popular Narrative: 2% Overvalued

Phibro Animal Health’s most followed narrative sets a fair value of $48.50, slightly below the last close at $49.47. This puts the spotlight on what is driving that view.

The company's strong recent growth is heavily dependent on the integration of the acquired Zoetis Medicated Feed Additive business and related cost synergies, which are non-repeatable. Forward guidance suggests legacy product growth will slow to flat or low single digits, implying the current trajectory of accelerating revenue and EBITDA growth is unsustainable and likely to normalize, impacting revenue and earnings growth expectations.

To understand what is baked into that fair value beyond one acquisition story, the narrative leans on specific revenue trends, margin shifts, and a tighter earnings profile that are worth seeing in full.

Result: Fair Value of $48.50 (OVERVALUED)

However, stronger than expected global protein demand or faster progress from the Phibro Forward program could support higher earnings than this narrative currently assumes.

Another View: Cash Flows Tell a Different Story

While the most popular narrative suggests Phibro Animal Health is about 2% overvalued at $48.50, our DCF model points in the opposite direction. On that view, the shares at $49.47 sit roughly 58.5% below an estimated future cash flow value of $119.16.

These two models give very different answers. Which set of assumptions do you find more convincing regarding Phibro’s future cash generation?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Phibro Animal Health for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With the mixed messages from different valuation views, are you leaning bullish or cautious on Phibro? Act while the data is fresh and weigh both the upside and the concerns by checking the 3 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Phibro is already on your radar, it makes sense to widen your watchlist with fresh ideas surfaced by the Simply Wall St stock screener.

• Spot potential value opportunities early by scanning our list of 48 high quality undervalued stocks that combine quality with attractive pricing.
• Strengthen your defensive side by checking out 68 resilient stocks with low risk scores, focused on companies with more resilient risk profiles.
• Stay ahead of the crowd by browsing a screener containing 26 high quality undiscovered gems that the market might not be paying close attention to yet.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.